Novartis is trading at $158.43, up 4.84% after hours; the supplied indicators do not establish a cause for the rebound.

  • On October 23, Novartis reported six-year Kisqali data showing an approximately 20% lower risk of death versus endocrine therapy alone.
  • It also presented Phase III remibrutinib results; reports said U.S. shares fell during the session after MS data showed less flare-up reduction than a Roche rival.
  • Supplied market indicators were mixed, offering no clear same-direction explanation.